Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 162.24% from the company’s previous close.

Separately, JMP Securities started coverage on shares of Werewolf Therapeutics in a report on Wednesday, April 3rd. They issued a “mkt outperform” rating and a $12.00 target price for the company.

Werewolf Therapeutics Trading Down 4.3 %

Shares of NASDAQ:HOWL opened at $5.72 on Monday. Werewolf Therapeutics has a 52-week low of $1.57 and a 52-week high of $8.19. The stock has a market capitalization of $247.96 million, a price-to-earnings ratio of -5.25 and a beta of 0.71. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14. The stock’s 50-day simple moving average is $6.18 and its two-hundred day simple moving average is $4.70.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The business had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.75 million. Analysts expect that Werewolf Therapeutics will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in HOWL. Certuity LLC bought a new position in shares of Werewolf Therapeutics during the 4th quarter valued at approximately $39,000. Financial Perspectives Inc raised its stake in Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after purchasing an additional 3,000 shares in the last quarter. Denali Advisors LLC bought a new stake in Werewolf Therapeutics during the first quarter worth approximately $172,000. PFM Health Sciences LP grew its holdings in Werewolf Therapeutics by 35.6% during the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after purchasing an additional 909,895 shares during the last quarter. Finally, Lighthouse Investment Partners LLC purchased a new position in Werewolf Therapeutics during the 4th quarter valued at $87,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.